- Home
- ACTU vs CHRS Comparison
ACTU vs CHRS Comparison
Compare ACTU & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACTU
- CHRS
- Stock Information
- Founded
- ACTU 2015
- CHRS 2010
- Country
- ACTU United States
- CHRS United States
- Employees
- ACTU N/A
- CHRS N/A
- Industry
- ACTU
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACTU
- CHRS Health Care
- Exchange
- ACTU NYSE
- CHRS Nasdaq
- Market Cap
- ACTU 135.0M
- CHRS 112.5M
- IPO Year
- ACTU 2024
- CHRS 2014
- Fundamental
- Price
- ACTU $7.47
- CHRS $0.76
- Analyst Decision
- ACTU Strong Buy
- CHRS Buy
- Analyst Count
- ACTU 1
- CHRS 3
- Target Price
- ACTU $20.00
- CHRS $4.68
- AVG Volume (30 Days)
- ACTU 85.1K
- CHRS 1.2M
- Earning Date
- ACTU 05-15-2025
- CHRS 08-07-2025
- Dividend Yield
- ACTU N/A
- CHRS N/A
- EPS Growth
- ACTU N/A
- CHRS N/A
- EPS
- ACTU N/A
- CHRS N/A
- Revenue
- ACTU N/A
- CHRS $272,251,000.00
- Revenue This Year
- ACTU N/A
- CHRS N/A
- Revenue Next Year
- ACTU N/A
- CHRS $132.69
- P/E Ratio
- ACTU N/A
- CHRS N/A
- Revenue Growth
- ACTU N/A
- CHRS 19.87
- 52 Week Low
- ACTU $5.51
- CHRS $0.66
- 52 Week High
- ACTU $11.99
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- ACTU N/A
- CHRS 40.60
- Support Level
- ACTU N/A
- CHRS $0.74
- Resistance Level
- ACTU N/A
- CHRS $0.79
- Average True Range (ATR)
- ACTU 0.00
- CHRS 0.05
- MACD
- ACTU 0.00
- CHRS 0.00
- Stochastic Oscillator
- ACTU 0.00
- CHRS 12.76
About ACTU ACTUATE THERAPEUTICS INC
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.